Novo Nordisk wins Netherlands GLP-1 compounding lawsuit
A Dutch court ordered a compounding pharmacy to stop selling an unapproved nasal spray version of semaglutide, upholding Novo Nordisk's patent rights.Summary
The District Court of The Hague issued a preliminary injunction against Breda-based Ceban Ziekenhuisfarmacie, requiring it to cease distribution of its compounded nasal spray semaglutide product, Semanova, which infringes Novo Nordisk's supplementary protection certificate for semaglutide. The court ruled that despite the expiration of the EU compound patent, the Dutch SPC remains in force until 2031, and compounding for bulk distribution violates Dutch patent law and EU regulations. Novo Nordisk emphasized that the decision protects patient safety and intellectual property rights, noting there are no approved nasal spray formulations of semaglutide globally. The case highlights the limits of pharmacy exemptions under the Dutch Patent Act and reinforces that compounding cannot be used to market unapproved drugs at scale, even amid demand for GLP-1 medications.
(Source：Pharmaphorum News)